NATAP: Glasow Reports-Metabolics/Hypertension/Diabetes

[Guest guest]

Glasgow Conference

Report on Metabolics, Metabolic Syndrome, Hypertension, Lipids, Diabetes

http://www.natap.org

d4T and Lipodystrophy Raise Diabetes Risk in D:A:D Cohort; Nevirapine Protects - Written for NATAP by Mark Mascolini (11/15/06)

The Metabolic Syndrome at Baseline in the D:A:D study 20% (11/15/06)

What's Better for High Lipids: Antilipid Drugs or NNRTI Switch? (11/16/06)

No Higher Risk of Toxicity-Related ART Stops in Older People - Written for NATAP by Mark Mascolini (11/16/06)

Antilipid Tactics, Diabetes, and Abacavir Reactions: (1) prescribe a lipid lowering drug or switch to NNRTI; (2) Atazanavir, lipids, and cardiovascular risk; (3) antilipid drug rosuvastatin; (4) Diabetes risk factors in D:A:D: d4T, ddI, AZT increase risk, nevirapine protective; (5) abacavir genetic testing prevents hypersensitivity reaction - Written for NATAP by Mark Mascolini (11/27/06)

Hypertension in HIV (11/27/06)

Antiretrovirals May be Double-Edged Sword for Liver Fibrosis: glucose levels associated with advancing fibrosis and increased CD4 count associated with slower fibrosis progression - Written for NATAP by Mark Mascolini (11/16/06)